



The tablets produced with Exentis' 3D technology are special because their active ingredient delivery profile can be freely adjusted in the human body. Image credit: Exentis

Exentis enables large-scale production of innovative tablets

11 September 2023 12:09

Related partners

[Exentis Group AG](#)

Stetten – Exentis' 3D technology can further accelerate the distribution of tablets with customizable drug delivery profiles. Market opportunities for the Swiss Exentis Group AG in this business area are very high, according to an analysis.

With its 3D cold printing process, [Exentis Group AG](#) enables the greatest production volumes of tablets with customizable active ingredient delivery profiles. This is the finding of an industry study by the management consultancy [Roland Berger](#). Exentis is the leading provider of a 3D technology platform for industrialized additive manufacturing. It enables clean room applications such as tablets or even industrial parts to be manufactured millions of times over on one 3D production system. Exentis' strategic business areas are Pharma & Medtech, New Energy and Ultra-fine Structures.

The tablets produced with Exentis' 3D technology are special because their active ingredient delivery profile can be freely adjusted in the human body. This leads to more efficient drug delivery and greater comfort during ingestion, according to the study. As well as human medicine, areas of application include veterinary medicine and nutritional supplements.

These innovative tablets can be used for medical indications in the field of neurology with epilepsy, Parkinson's disease or migraine; in endocrinology with diabetes; and in cardiology, oncology and psychiatry. In terms of key indications, the experts identified a market potential of well over 100 billion Swiss francs and a growth forecast of around 7 per cent annually until 2026.

The New York-based company [Laxxon Medical](#), which has been a member of the Exentis 3D Community since 2017, has acquired an exclusive global license from Exentis for the development, production and commercialization of drugs manufactured using Exentis technology. Laxxon Medical has already granted several sublicenses for individual indications or active ingredients to renowned US pharmaceutical companies. In March 2023, Laxxon concluded a long-term strategic cooperation agreement with [Hovione](#), a leading producer in the pharmaceutical industry. ce/yvh

Supporting partner





SWISS PAVILION DIGITAL

< Swiss aviation industry well represented at the Paris Air Show

20 June 2023 14:44

Le Bourget - In total, 40 Swiss companies are in attendance at the Paris Air Show. The SWISS Pavilion is being organized by Swissmem. The official Swiss delegation is headed up by the National Armaments Director Martin Sonderegger.

[Paris Airshow](#)

[more](#)

Keepears continues to grow

15 June 2023 16:11

Allschwil - Keepears, based in the canton of Basel-Landschaft, is planning to expand further in Europe and the Middle East. It is set to open a site in Abu Dhabi this year, and another in France, where it intends to step up its activities of clients' support as well as research and development activities focusing on hearing systems for extreme environments.

[Paris Airshow](#)

[more](#)

Carbomill expands aerospace offering

15 June 2023 12:04

Seon - Carbomill AG is now offering the production process of electrical discharge machining (EDM) to the aerospace industry. The mechanical high-end processing specialist based in Aargau has enlarged its machine fleet to do so.

[Paris Airshow](#)

[more](#)

Airwork & Heliseilerei bring many production steps in house

15 June 2023 11:15

Immensee - Airwork & Heliseilerei has established more and more competences and machines in Immensee in the canton of Schwyz over recent years. This has shortened production routes and supply chains and quantifiably improved processes. It also enables even greater consideration of client wishes.

[Paris Airshow](#)

[more](#)

Bula Technologie presents innovative polishing machine

Casram launches manufacturing cell for

Xovis controlling passenger flows in Thailand

About

Terms and conditions

Privacy policy

[Newsletter](#)
powered by [Infohalle](#)

swiss export
Association
Staffelstrasse 8
CH-8045 Zürich

info@swiss-export.com
[+41\(0\)44 204 34 84](tel:+410442043484)

Café Europe.
Nachrichtenagentur AG
Metzggasse 14
CH-8400 Winterthur

redaktion@cafe-europe.info
[+41\(0\)44 306 47 60](tel:+410443064760)